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Cardiac resynchronization therapy (CRT) is an estab-lished treatment for selected patients with heart  failure.1–4 
However, clinical response remains highly variable.5 Even 
among patients with left bundle branch block (LBBB), there 
is heterogeneity in the location of conduction block and result-
ing left ventricular (LV) activation pattern.6,7 Two broad pat-
terns of LV activation have been described: type I activation, 
with slow propagation from the septum to lateral wall, and 
type II activation, with a U-shaped activation pattern resulting 
from a line of functional conduction block. A type II activation 
pattern would be expected to be more amenable to correction 
by LV stimulation, and indeed this pattern is associated with a 
favorable response to CRT.8 Another key determinant of CRT 
response is the presence, location and burden of myocardial 
scar, and the position of the LV lead with respect to these 
regions.9–12 Even in patients with nonischemic cardiomyopathy 
(NICM), there may be significant variability in CRT response 
according to LV pacing site,13 which may be because of the 
presence of zones of slow conduction.14 Endocardial LV stim-
ulation represents an alternative approach to avoid these areas 
without the constraints of the coronary venous anatomy and 
may be more effective than conventional epicardial CRT via 
the coronary sinus (CS).15 Another strategy to improve CRT 
response is to position 2 LV leads to perform multisite LV 
pacing and simultaneously recruit a larger volume of myocar-
dium. Conflicting results of the acute hemodynamic response 
(AHR) to dual-site pacing have been reported.16–18
Clinical Perspective on p 897
We hypothesized that endocardial and multisite LV 
stimulation may be most beneficial in patients unlikely to 
benefit from standard CRT, including those with myocardial 
Background—There is considerable heterogeneity in the myocardial substrate of patients undergoing cardiac resynchronization 
therapy (CRT), in particular in the etiology of heart failure and in the location of conduction block within the heart. This 
may account for variability in response to CRT. New approaches, including endocardial and multisite left ventricular (LV) 
stimulation, may improve CRT response. We sought to evaluate these approaches using noncontact mapping to understand 
the underlying mechanisms.
Methods and Results—Ten patients (8 men and 2 women; mean [SD] age 63 [12] years; LV ejection fraction 246%; QRS 
duration 161 [24] ms) fulfilling conventional CRT criteria underwent an electrophysiological study, with assessment of 
acute hemodynamic response to conventional CRT as well as LV endocardial and multisite pacing. LV activation pattern 
was assessed using noncontact mapping. LV endocardial pacing gave a superior acute hemodynamic response compared 
with conventional CRT (26% versus 37% increase in LV dP/dt
max
, respectively; P<0.0005). There was a trend toward further 
incremental benefit from multisite LV stimulation, although this did not reach statistical significance (P=0.08). The majority 
(71%) of patients with nonischemic heart failure etiology or functional block responded to conventional CRT, whereas those 
with myocardial scar or absence of functional block often required endocardial or multisite pacing to achieve CRT response.
Conclusions—Endocardial or multisite pacing may be required in certain subsets of patients undergoing CRT. Patients 
with ischemic cardiomyopathy and those with narrower QRS, in particular, may stand to benefit. (Circ Arrhythm 
Electrophysiol. 2012;5:889-897.)
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scar and a type I LV activation pattern. We set out to examine 
the underlying mechanisms whereby such novel pacing 
techniques may improve CRT response in relation to the 
underlying electric activation pattern and presence or absence 
of scar using noncontact mapping, cardiac magnetic resonance 
(CMR), and acute hemodynamic measurements.
Methods
Patients
St Thomas' Hospital Research Ethics Committee approved the study, 
and all patients provided written informed consent. Eligible patients 
were ≥18 years old and fulfilled conventional CRT criteria.19 Patients 
with hemodynamically significant aortic valve disease, mechanical 
right heart valve or aortic valve, peripheral vascular disease, atrial 
arrhythmia, or contraindication to anticoagulation were excluded 
because they would not be able to undergo the protocol for the elec-
trophysiology/noncontact mapping study (which was not part of 
routine CRT work-up). The study protocol was performed at least 1 
week before standard CRT implantation. Patients with ischemic and 
NICM were studied, and the etiology of heart failure was confirmed 
on the basis of clinical history, 12-lead ECG, coronary angiogram, 
and CMR imaging.
Cardiac Magnetic Resonance
CMR was used to quantify LV function and volumes. Late gadolini-
um enhancement CMR imaging was performed after the administra-
tion of a gadolinium-based contrast agent to assess myocardial scar or 
fibrosis. CMR was performed with a 1.5-T scanner (Philips Medical 
Systems), and late enhancement imaging was performed 15 to 20 
minutes after the administration of 0.1 to 0.2 mmol/kg gadopentetate 
dimeglumine (Magnevist; Bayer Healthcare) using conventional in-
version recovery techniques.20
Electrophysiological Study
Procedures were performed in a hybrid x-ray/magnetic resonance 
 imaging interventional cardiac catheter laboratory. Patients were se-
dated using diazepam (5–10 mg). Bilateral femoral venous  access was 
used to place 5F Supreme quadripolar catheters (St. Jude Medical, 
St. Paul, MN) to the high right atrium, the bundle of His, and right 
ventricular apex to perform atrial and ventricular sensing and pac-
ing. A 2.5F Pathfinder multipolar catheter (Cardima Inc, Fremont, 
CA) was introduced to the coronary sinus via an 8F SL3 sheath 
(St. Jude Medical) and passed to a posterolateral or lateral branch of 
the CS to perform epicardial LV pacing to replicate standard CRT. A 
9F EC1000 noncontact mapping array (St. Jude Medical) was passed 
via the femoral artery retrogradely across the aortic valve to the LV 
cavity. Through the other femoral artery, a 6F Livewire (St. Jude 
Medical) steerable decapolar catheter was passed to the LV cavity to 
reconstruct the chamber geometry, along with a Certus PressureWire 
(Radi Medical Systems, Uppsala, Sweden). This is a high fidelity 
wire, acquiring data at 400 Hz. Intravenous heparin (70 U/kg) was 
given to achieve systemic anticoagulation (target activated clotting 
time, 300–350 seconds). A left anterior oblique fluoroscopic view of 
the catheters in the heart at the time of the electrophysiological study 
is shown in Figure 1.
A pacing protocol was performed in a random fashion (100 beats 
per minute, atrioventricular delay 100 ms in all configurations, in-
terventricular simultaneous): AAI (baseline), DDD right ventricle, 
and DDD BIV-CS (to reproduce conventional epicardial CRT via the 
posterolateral vein). LV endocardial pacing was per formed: DDD LV 
endocardial (LV-EN) and DDD BIV endocardial (right ventricular 
and LV-EN: BIV-EN). In all modes involving LV endocardial pacing, 
we positioned the LV rove catheter in at least 3 different endocar-
dial positions: anterior, lateral, and posterior. Capture was verified in 
VVI mode at each ventricular pacing site. To exclude fusion  between 
intrinsic activation and LV pacing, both QRS morphology and the 
LV activation wave front on noncontact mapping were analyzed. 
Multisite LV pacing was performed (TRI-V), which was a combina-
tion of BIV-CS and LV-EN pacing, with simultaneous stimulation for 
all ventricular pacing sites. TRI-V stimulation was performed at each 
new LV-EN site.
Noncontact Mapping
The EnSite 3000 system (St. Jude Medical), with the EC1000 mul-
tielectrode array mapping catheter, uses the inverse solution method 
to reconstruct endocardial unipolar potentials within the LV cav-
ity. The accuracy of this technique has been validated previously.21 
Endocardial maps were obtained in sinus rhythm and in each pac-
ing configuration. The virtual unipolar electrograms recorded from 
the endocardial surface were used to measure the LV activation time 
(LVAT). The electrograms were acquired at 1200 Hz, giving a tem-
poral resolution of 0.83 ms. The high-pass filter was set at 8 Hz. The 
onset of activation was defined as the first peak negative dV/dt at any 
point in the left ventricle. The end of LV activation was defined as the 
time of the latest peak negative unipolar electrogram on the virtual 
endocardial surface. The activation pattern of the LV was determined 
on the basis of the presence or absence of lines of functional block.6
Figure 1. Left anterior oblique fluoroscopic image 
of noncontact mapping array and electrophysi-
ological catheters in situ during a typical case.  
The color overlay shows left ventricular (LV) 
 endocardial lead positions in magenta, right 
 ventricular (RV) quadripolar electrodes in blue, tip 
of coronary sinus multipolar electrode in cyan, and 
scar  segmented from cardiac magnetic resonance 
 overlaid in red onto fluoroscopic image.
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Hemodynamic Assessment
Hemodynamic parameters were assessed at baseline (in AAI mode) 
and in each pacing mode once steady-state pacing had been achieved 
for a minimum of 1 minute. We used the pressure wire to derive real-
time mean peak LV dP/dt
max
 as a marker of LV contractility, with 
3 measurements in each pacing mode taken over a minimum of 10 
seconds each. An increase in LV dP/dt
max
 of ≥10% from baseline AAI 
pacing was considered to represent positive AHR.22
Statistical Analysis
Continuous variables are expressed as mean (SD). Data were ana-
lyzed using generalized estimating equations using an exchangeable 
correlation structure to explore the extent of differences between pac-
ing methods. All pacing methods were compared with each other, and 
to avoid type 1 errors, P values were corrected using the Bonferroni 
adjustment. To perform a Bonferroni correction for each P value, the 
P value was divided by the number of comparisons made. For LV 
dP/dt
max
, there were 5 comparisons between pacing modes; therefore, 
P<0.01 was considered significant at the 5% level.
Results
Patient Demographics
Patient demographics are shown in Table 1. All patients had 
LBBB and were in New York Heart Association class III, 
despite optimal drug treatment. The invasive nature of the 
study (excluding patients with significant peripheral vas-
cular disease) resulted in a predominance of patients with 
NICM.
AHR to Pacing
Ten patients were studied. The mean AHR at the optimal 
pacing site is shown in Figure 2. In sinus rhythm, the mean 
(SD) LV dP/dt
max
 was 829 (161) mm Hg/s, increasing by 5% 
to 870 (201) mm Hg/s with AAI pacing, which was used as 
a baseline to assess other measurements to control for the 
effect of heart rate. There was no significant change from 
baseline with right ventricular endocardial pacing (861 
[234] mm Hg/s). With BIV-CS pacing, there was a 26% 
increase from baseline to 1043 (378; 95% CI, 17.1–30.3) 
mm Hg/s. With LV-EN pacing, there was a greater increase 
from baseline of 37% m to 1135 (412; 95% CI, 29.4–42.5) 
mm Hg/s, which was similar to BIV-EN pacing at 1114 
(410; 95% CI, 29.3–42.4) mm Hg/s. The greatest AHR was 
seen with TRI-V pacing, with a 47% increase from baseline 
to 1207 (464; 95% CI, 35.0–48.2) mm Hg/s. There was a 
statistically significant difference between right ventricular 
and all other pacing modes (P<0.0001) and a significant 
improvement compared with BIV-CS pacing with all 
LV-EN pacing configurations (P<0.0005). There was an 
improvement as a result of TRI-V pacing compared with 
other LV-EN pacing modes, which did not reach statistical 
significance (P=0.08).
Effect of LV Pacing Site on AHR
The overall variability in hemodynamic response according 
to LV-EN pacing site (anterior versus posterior versus 
lateral) was not statistically significant (P=0.073). The mean 
difference in AHR between LV-EN and BIV-EN across 
pacing site was 0.93 (95% CI, −6.0 to 7.9), and the mean 
difference between LV-EN and TRI-V was 8.53 (95% CI, 
1.56–15.51). The mean difference between the anterior 
and lateral pacing sites was 2.11 (95% CI, 5.52–9.73) and 
between the anterior and posterior sites was 3.00 (95% CI, 
−10.24 to 4.24).
Effect of Heart Failure Etiology on AHR 
Seven patients had NICM with no scar on late gadolinium 
enhancement CMR. Patients with NICM had a mean increase 
from baseline of 214 (224) mm Hg/s (26%) with BIV-CS pac-
ing, 316 (254) mm Hg/s (37%) with LV-EN, 295 (245) mm 
Hg/s (36%) with BIV-EN, and 388 (304) mm Hg/s (47%) with 
TRI-V pacing. Five of the 7 (71%) patients with NICM were 
acute responders with standard BIV-CS pacing. Notably, the 
2 patients with NICM who were nonresponders to BIV-CS 
pacing had a type I activation pattern, and both responded to 
endocardial and multisite (TRI-V) stimulation. Patients with 
ischemic cardiomyopathy (ICM) had a mean increase in LV 
dP/dt
max
 of 108 (74) mm Hg/s (12%) with standard CRT (BIV-
CS pacing) compared with 249 (103) mm Hg/s (26%) with 
LV-EN, 312 (97) mm Hg/s (32%) with BIV-EN, and 391 (148) 
Table 1. Baseline Characteristics of the Study Population
Parameter Mean (SD) or Number
Age, y 63 (12)
Sex (M:F) 8:2
NYHA class III 10
MLWHFQ 45 (27)
Etiology (ischemic:nonischemic) 3:7
LVEF, % 24 (6)
QRS duration, ms 161 (24)
LVEDV, mL 273 (59)
NYHA indicates New York Heart Association; MLWHFQ, Minnesota Living With 
Heart Failure Questionnaire; LVEF, left ventricular ejection fraction; LVEDV, left 
ventricular end-diastolic volume (calculated using Simpson biplane method).
Figure 2. Mean dP/dtmax for all pacing modalities in all 10 
patients. This is displayed as the change in mean peak dP/dtmax 
resulting from pacing at the optimal site in each pacing configu-
ration, compared with baseline (AAI pacing). LV indicates left 
ventricular; RV, right ventricular; BIV, biventricular; TRI-V, simul-
taneous BIV-CS and LV endocardial (EN).
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mm Hg/s (40%) with TRI-V pacing (Figure 3). After adjusting 
for the mode of pacing, the difference in AHR between ICM 
and NICM was not significant (mean difference, −7.82; 95% 
CI, −28.93 to 13.28; P=0.47) (Figure 3 and Table 2).
Stimulation in Ischemic Patients and  
Relationship to Scar
All the 3 patients with ICM exhibited late gadolinium 
enhancement on CMR. One patient with ICM had type I acti-
vation with a lateral line of block. With standard CS pacing, 
this patient was a nonresponder (5% increase in LV dP/dt
max
) 
but became an acute responder with endocardial pacing, with 
a response of 34% that increased to 45% with TRI-V stimula-
tion. In this patient, the epicardial CS lead was overlying a 
region of scar/slow conduction defined by noncontact map-
ping/CMR. The second patient with ICM had a type I activa-
tion pattern and had an AHR of 19% with BIV-CS pacing but 
a more marked AHR of 39% with endocardial stimulation and 
a further rise to 51% with TRI-V pacing. In this patient, the 
CS lead was not located in an area of scar or slow conduction. 
The third patient with ICM exhibited type II activation and 
was a hemodynamic nonresponder with BIV-CS pacing (9%) 
but improved to 14% with endocardial and to 24% with TRI-V 
pacing. In this patient, the CS lead was not located in an area 
of scar or slow conduction. Thus, all patients with ICM had an 
incremental benefit with endocardial and TRI-V pacing, and 2 
of 3 classified as nonresponders with standard BIV-CS pacing 
responded to endocardial or TRI-V pacing. In only 1 patient 
was the CS lead located in an area of scar/slow conduction. 
Figure 1 shows an example of a patient with ICM, with the 
location of the CS lead and endocardial pacing sites marked, 
as well as their relationships to a myocardial scar.
Importance of Activation Pattern
Five patients had type I and 5 had type II activation on the 
basis of noncontact mapping (Figures 4 and 5). Patients with 
type I activation had a mean increase in LV dP/dt
max
 of 176 
(277) mm Hg/s (15%) with BIV-CS pacing compared with 
347 (284) mm Hg/s (33%) and 361 (276) mm Hg/s (35%) with 
LV-EN and BIV-EN, respectively, and 443 (327) mm Hg/s 
(43%) with TRI-V pacing. In patients with type II activation, 
there was a mean increase of 188 (82) mm Hg/s (28%) with 
BIV-CS pacing compared with 229 (120) mm Hg/s (35%) 
with LV-EN, 224 (87) mm Hg/s (33%) with BIV-EN, and 319 
(180) mm Hg/s (45%) with TRI-V pacing. Of patients with 
a type I pattern, only 2 of 5 (40%) were classified as acute 
responders with standard BIV-CS pacing; however, 5 of 5 
patients (100%) responded with endocardial or TRI-V pacing. 
Of the patients with type II activation, 4 of 5 (80%) were acute 
responders with BIV-CS pacing; the 1 nonresponder (ICM) 
responded with endocardial and TRI-V pacing. There was a 
lesser incremental benefit with endocardial or TRI-V pacing 
compared with BIV-CS pacing in patients with type II activa-
tion. After adjusting for the effect of pacing mode, patients 
with type I activation did not differ significantly in the degree 
of response from those with type II activation (mean differ-
ence, 1.39; 95% CI, −11.55 to 14.34; P=0.83; Figure 5).
Effect of Pacing on QRS Duration and LVAT
Results are shown in Figure 6 and Table 3. There was varia-
tion in QRS duration as a result of pacing mode (P<0.0001), 
which was of borderline significance after adjusting for acti-
vation pattern, with a mean difference of 25.34 (95% CI, 
−0.35 to 51.04; P=0.053). In a similar way, LVAT also varied 
significantly overall (P=0.0003), but the effect of the activa-
tion pattern was not significant (mean difference, 3.01; 95% 
CI, −10.45 to 16.46; P=0.66)
Discussion
LV Activation Pattern and Hemodynamic  
Response to Pacing
Our patients with LBBB and LV dysfunction exhibit varied 
hemodynamic responses to different pacing modalities, 
which were related to both the underlying etiology and the 
type of LV activation. Patients with ICM and type I activation 
Figure 3. Acute hemodynamic response (percentage change in 
left ventricular [LV] dP/dtmax from AAI mode) in patients with isch-
emic cardiomyopathy (ICM) and nonischemic cardiomyopathy 
(NICM). RV indicates right ventricular; BIV, biventricular; TRI-V, 
simultaneous BIV-CS and LV endocardial (EN).
Table 2. Effect of Heart Failure Etiology and Activation 
Pattern on Acute Hemodynamic Response
Patient Etiology Scar
Activation 
Pattern
Responder 
BIV-CS
Responder 
Endocardial
Responder 
TRI-V
1 NICM N II Y Y Y
2 NICM N II Y Y Y
3 NICM N I N Y Y
4 ICM Y I N Y Y
5 NICM N II Y Y Y
6 ICM Y I Y Y Y
7 NICM N II Y Y Y
8 NICM N I N Y Y
9 ICM Y II N Y Y
10 NICM N I Y Y Y
TRI-V indicates simultaneous BIV-CS and LV endocardial; NICM, 
nonischemic cardiomyopathy; ICM, ischemic cardiomyopathy.
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exhibited a lesser response to conventional CS-based CRT 
than patients with NICM and a type II activation pattern. 
However, this difference was not found to be statistically 
significant because the study was not powered to address 
this issue. Importantly, there were patients classified as 
hemodynamic nonresponders with standard CRT who 
responded to non standard forms of CRT (endocardial pacing 
and multisite LV stimulation). These patients tended to have 
ICM and a type I LV activation pattern, which are recognized 
markers of poor CRT response. In comparison, patients with 
NICM and a type II activation pattern typically identified as 
responding well to standard CRT did not require alternative 
forms of non–CS-based pacing to derive AHR. Notably, the 
2 patients with NICM who were nonresponders to CS pacing 
had a type I activation pattern.
Our patients with type II activation tended to have a broader 
QRS (174 versus 152 ms; P=0.09) but similar LVAT (79 versus 
82 ms). There was a good correlation between QRS duration 
and LVAT (r=0.64) in patients with type I activation. This 
is intuitive because this group is thought to have relatively 
normal transseptal activation and slow homogeneous wave 
front propagation.6 In contrast, there was a poor correlation 
Figure 4. Activation patterns 
 characterized by noncontact mapping. 
Upper panel: Type I activation pattern. 
The  isochronal map shows a smooth 
 propagation of the activation wave front 
from left ventricular (LV) septum to lateral 
wall. Lower panel: Type II  activation 
pattern. The  isochronal map shows a 
line of block in the anterior wall with the 
activation wave front passing around 
the inferior LV wall before it reaches the 
 lateral wall.  
Figure 5. Hemodynamic response to pacing according to base-
line left ventricular (LV) activation pattern. RV indicates right ven-
tricular; BIV, biventricular; TRI-V, simultaneous BIV-CS and LV 
endocardial (EN).
Figure 6. QRS duration by pacing mode. RV indicates right ven-
tricular; BIV, biventricular; TRI-V, simultaneous BIV-CS and LV 
endocardial (EN).
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between LVAT and QRS duration in patients with type II 
activation (r=0.17), which is likely to reflect variation in 
the location and extent of functional conduction delay. One 
would, therefore, expect type II activation to be associated 
with a broader QRS complex and that this conduction delay 
may be more readily overcome by conventional CRT. In 
contrast, type I activation constitutes a substrate that is less 
readily improved by conventional CRT because propagation 
is homogeneously slow from the septum to the lateral wall 
without a line of functional conduction block.
Comparison With Previous Studies
LV Activation
Heterogeneous ventricular activation in patients with LBBB 
using noncontact mapping was previously described by Auric-
chio et al6. The majority of patients evaluated had a type II/U-
shaped activation pattern resulting from a line of functional 
conduction block. In these patients, an anterior line of func-
tional block was associated with longer QRS duration and was 
more readily overcome with pacing the lateral LV, keeping 
with the idea that this substrate is more readily treated with 
conventional CRT. This has been borne out in larger-scale 
studies, such as Multicenter Automatic Defibrillator Implanta-
tion Trial (MADIT)-CRT,23 in which patients with QRS dura-
tion >150 ms derived a greater degree of clinical benefit.
Fung et al8 also found that the majority (15/23) of their 
patients with LBBB had type II conduction, which was asso-
ciated with a greater frequency of both clinical and echo-
cardiographic response to CRT. The authors found that type 
I activation was more common in patients with an ischemic 
(63%) versus a nonischemic etiology (20%), and they hypoth-
esized that areas of infarcted myocardium causing morpho-
logically based fixed conduction block may explain why 
patients with ICM may require alternative approaches to the 
delivery of CRT.
Importance of LV Pacing Site
We did not find statistically significant differences among 
anterior, lateral, and posterior pacing sites in biventricular 
pacing configurations. This is in keeping with the findings of 
the MADIT-CRT study, in which the degree of benefit from 
CRT was similar in patients with anterior, lateral, and poste-
rior LV lead positions.24
Endocardial and Multisite Pacing
The AHR to multisite LV pacing (in different branches of 
the CS) has been reported previously. Pappone et al16 studied 
the AHR to dual-site pacing in 14 patients and demonstrated 
improvements in systolic function that were associated 
with a greater reduction in paced QRS duration. Padeletti17 
performed dual-site LV pacing in 12 patients and concluded 
that the addition of a second LV lead had no incremental 
benefit over standard CRT if the LV lead was optimally 
positioned and the atrioventricular and interventricular 
delays were optimized. In a study of 26 patients with atrial 
fibrillation who were implanted with a CRT device with 2 LV 
leads, the investigators of the Triple Resynchronization In 
Paced Heart Failure Patients (TRIP-HF) study demonstrated 
improvements in reverse LV remodeling resulting from dual-
site LV pacing over single-site LV pacing in conjunction 
with CRT during the 9-month follow-up.25 Furthermore, 4 of 
10 patients in the TRIP-HF study who did not have reverse 
LV remodeling with single-site LV pacing responded with 
dual-site LV pacing.
Other investigators have shown endocardial pacing to 
be superior to epicardial CRT in patients with NICM13 and 
ICM.15 One key mechanism may be that this approach facil-
itates pacing outside areas of scar/slow conduction because 
greater area of the myocardium is accessible when lead 
delivery is not constrained by the coronary venous anat-
omy. In one of our ischemic patients, the CS lead was in an 
area of slow conduction, which may explain the beneficial 
response to endocardial or multisite pacing. However, in the 
other 2 ischemic patients, the CS lead was not in a region 
of slow conduction or scar. These findings, albeit from a 
small number of patients, suggest that the mechanism of 
benefit with TRI-V may be that the mode of stimulation 
influences LV mechanics and loading conditions, rather 
than simply overcoming the proximity of the leads in rela-
tion to scar.
In addition, there are other potential physiological ben-
efits from endocardial pacing,26 which, by engaging the 
subendocardial Purkinje network, reproduces the gradient 
of LV contraction in systole in an endocardial to epicar-
dial direction.27 This may result in more rapid myocardial 
recruitment, maximizing the contractile response of the via-
ble recruited myocytes. Strik et al28 have recently reported 
Table 3. Effect of Pacing on QRS duration and LVAT
Pacing Configuration AAI RV BIV-CS LV-EN BIV-EN TRI-V
QRS duration, ms
Mean (SD)
All 165 (23) 196 (33) 148 (20) 162 (37) 159 (30) 141 (30)
Type I 152 (12) 178 (16) 160 (4) 152 (29) 159 (26) 146 (20)
Type II 174 (27) 208 (46) 134 (29) 161 (49) 155 (32) 129 (37)
LVAT, ms
Mean (SD)
All 81 (18) 85 (17) 78 (22) 91 (24) 83 (22) 79 (19)
Type I 82 (20) 92 (8) 85 (25) 80 (5) 85 (4) 74 (17)
Type II 79 (20) 77 (21) 69 (23) 105 (32) 68 (17) 77 (22)
LVAT indicates left ventricular activation time; RV indicates right ventricular; BIV, biventricular; TRI-V, simultaneous 
BIV-CS and LV endocardial (EN).
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in this journal the results of their work on endocardial LV 
pacing in a chronic canine heart failure model. The authors 
demonstrated improved hemodynamics as a result of LV 
endocardial pacing compared with conventional epicardial 
CRT, which could be explained by the shorter path length 
and more rapid conduction resulting from endocardial LV 
pacing. In keeping with our findings, the authors did not find 
a significant reduction in endocardial LVAT with endocar-
dial pacing; however, total LVAT, as well as transmyocar-
dial LVAT, was reduced. Our results support the superiority 
of endocardial pacing over CS pacing in certain patients 
and suggest a possible synergistic effect of simultaneous 
endocardial and epicardial stimulation (TRI-V stimula-
tion) over an endocardial site alone. This may be because 
of recruitment of a larger volume of myocardium and may 
also be explained on the basis of reducing the transmyo-
cardial conduction time. This would be expected to shorten 
the QRS duration while not greatly affecting the endocar-
dial LVAT. Indeed, our results suggest a greater reduction 
in QRS duration between BIV-EN and TRI-V pacing com-
pared with the difference in LVAT between BIV-EN and 
TRI-V, which may reflect the reduction in transmyocardial 
conduction.
Clinical Implications for CRT
Identification of a U-shaped LV activation pattern may allow 
better selection of optimal lateral wall LV lead placement and 
when absent may indicate a subgroup that should be consid-
ered for initial multipolar or endocardial LV pacing. An LV 
activation pattern is not always apparent from the surface 
ECG. However it would seem that the broader the QRS, the 
more likely the activation pattern will respond favorably to 
conventional CRT. Noncontact mapping is a highly invasive 
tool that is impractical for widespread use to determine CRT 
response, and use of other technologies, such as body sur-
face mapping, may hold some promise to define activation 
patterns.29
In this study, endocardial and multisite pacing were of 
benefit to patients with ICM and NICM. Intuitively, one 
might expect patients with ICM and scar to have more to 
gain with multisite stimulation because areas of block may 
be overcome with multiple stimulation sites. However, 
patients with NICM may also have areas of slow conduction 
or block, which may not be readily detected by current CMR 
techniques.30 Derval et al13 have shown that even in patients 
with NICM there is significant variability in hemodynamic 
response to CRT depending on the pacing site, which may be 
related to areas of slow conduction.
At present, there are several important limitations to the 
clinical use of endocardial LV pacing. First, the require-
ment for delivery of the endocardial LV lead poses technical 
challenges. There currently is no dedicated equipment for 
transseptal access using a superior approach, and transseptal 
puncture is almost universally performed with the femoral 
approach. If this approach is used, a second step is required 
to pass the lead across the interatrial septum, and several 
different strategies for this have been described.31–33 The sec-
ond issue is that an endocardial LV lead mandates formal 
anticoagulation and is likely to increase the risk of thrombo-
embolism. However, this risk is difficult to quantify because 
many patients who are considered eligible for endocardial 
LV stimulation are anticoagulated for another reason, most 
commonly coexistent atrial fibrillation or mechanical valve 
prosthesis. Third, there is potential for interference with 
mitral valve function as a result of crossing the valve appa-
ratus with the LV lead, and there may be an associated risk 
of endocarditis. In the event of device infection and should 
lead extraction be required, it is likely to require a surgical 
approach.
Study Limitations
Noncontact mapping relies on unipolar signal detection 
and may not reliably distinguish between signals from the 
opposite site of the septum because they are sensitive and 
reflect electrograms from the entire wall. Noncontact map-
ping may also be less accurate in the enlarged left ventricle. 
Given the invasive and complex nature of these clinical mea-
surements, we studied a small number of patients. There are 
definite trends; however, because of these small numbers it 
is not possible to determine whether these differences are 
clinically significant. In addition, this study is underpow-
ered to address the effect of etiology and activation pattern 
on CRT response. Therefore, this work raises mechanistic 
insights, but larger studies are required to investigate these 
issues further. A factor that is difficult to control for in such a 
small mechanistic study is the volume of viable myocardium 
available for recruitment during pacing; this would require 
a large population and normalization of the hemodynamic 
response to the volume of viable myocardium available for 
resynchronization.
Conclusions
A greater proportion of patients in this study derived acute 
hemodynamic benefit in response to endocardial and mul-
tisite (TRI-V) pacing. These were patients with ischemic 
heart disease and a type I activation pattern and less marked 
QRS prolongation. The hemodynamic effect seemed to be 
dependent on the activation pattern but not absolutely on 
the LVAT, suggesting discordance between electric and 
mechanical resynchronization. The effect of TRI-V pacing 
seemed to be incremental to the effect of endocardial pacing 
alone. This study highlights subgroups of patients who may 
respond to endocardial or multisite pacing. A large-scale 
trial is warranted to evaluate the effects of LV endocardial 
and multisite pacing to establish whether such alternative 
approaches should be considered in patients who have not 
responded to CRT.
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CLINICAL PERSPECTIVE
Response to cardiac resynchronization therapy (CRT) varies greatly among patients. Two key determinants of response 
are the heart failure substrate and the method of delivery of resynchronization. In this small mechanistic study, 10 patients 
with heart failure who were scheduled to undergo CRT were extensively investigated with cardiac magnetic resonance and 
noncontact mapping to identify areas of myocardial scar and to define the left ventricular (LV) activation pattern. A pac-
ing protocol was performed to include conventional CRT delivered from a lateral or posterolateral branch of the coronary 
sinus, as well as endocardial LV pacing at several different sites and multisite pacing from endocardial and coronary sinus 
sites simultaneously. The authors found that response rates to CRT delivered in a tributary of the coronary sinus was high in 
patients with nonischemic cardiomyopathy and in those with functional conduction block in the LV myocardium. However, 
subjects with an ischemic heart failure etiology or slow homogeneous LV activation patterns frequently required other forms 
of LV stimulation, such as endocardial or multisite pacing, to derive hemodynamic benefit. Although this is a small study, it 
raises the possibility that these patients (who typically have lower response rates to CRT) may derive response to CRT only 
with such novel pacing strategies. If this is borne out by larger studies, noninvasive assessment to identify these patients may 
help to optimize patient selection and tailor therapy.
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